Biosplice Therapeutics

Executive Summary

Biosplice Therapeutics is a private biotechnology company headquartered in San Diego, California, founded in 2012. The company focuses on leveraging the biology of alternative pre-mRNA splicing to develop small-molecule therapeutics. Alternative splicing allows a single gene to produce multiple protein variants with distinct or opposing functions, and dysregulation of this process is implicated in numerous diseases. Biosplice aims to correct splicing abnormalities by targeting the splicing machinery, thereby restoring normal protein function. While specific pipeline details are not publicly disclosed, the company's platform holds potential across oncology, genetic disorders, and other therapeutic areas. As a private entity, Biosplice operates without public financial disclosures, and its progress is tracked primarily through partnerships, funding rounds, and scientific publications. The company continues to advance its proprietary technology toward clinical validation.